Further support to this hypothesis came from the fact that signature for functionally active CD8+ T cells were higher in melanoma patients who responded to Ipilimumab or Nivolumab monotherapies [Figure 5D, data from CA209-038 study 59]. Here, CD8A is linked to melanoma.